Targeted Oncology interviews feature the world's leading oncologists sharing their insights on the latest news and advances in diagnostic testing, biomarkers, pathways, immunotherapy, and targeted therapeutics for better application into clinical practice.
Using MRD Negativity to Discontinue Maintenance Treatment in Multiple Myeloma
January 15th 2023In an interview with Targeted Oncology, Ben Derman, MD, discussed data from an ongoing clinical trial evaluating MRD-guided discontinuation of maintenance therapy in patients with multiple myeloma.
Read More
Gut Microbiome Shows Potential as New Option for Patients With Colorectal Cancer
January 11th 2023In an interview with Targeted Oncology, Patrick Wagner, MD, FACS, discussed the possibility of using the gut microbiome for patients with colorectal cancer, as well as his own research on the topic.
Read More
Addition of Polatuzumab to R-CHOP Improves Outcomes for Patients With DLBCL
January 10th 2023In an interview with Targeted Oncology, Gustavo Fonseca, MD, FACP, discussed the positive health-related quality of life findings in patients with diffuse large B-cell lymphoma from the POLARIX study.
Read More
Ongoing Trials Investigate Amivantamab Combinations for EGFR+ NSCLC
January 7th 2023Melina E. Marmarelis, MD, reports the study design of the Chrysalis-2 trial and ongoing trials researching the combination of amivantamab and lazertinib in patients with EGFR-mutated advanced non–small cell lung cancer.
Watch
Glofitamab Leads to Durable Complete Remissions in Relapsed/Refractory LBCL
January 6th 2023In an interview with Targeted Oncology, Cyrus M. Khan, MD, further discussed the background of the phase 1/2 trial and the potential use of glofitamab for patients with large B-cell lymphoma in the future.
Read More
Bringing Targeted Agents from Clinical Trials to the Clinic for Patients With Uterine Sarcoma
December 23rd 2022In an interview with Targeted Oncology, Matthew A. Ingham, MD, explains the uniqueness of uterine sarcomas and how years of research around these tumors have led to advances in precision medicine for patients.
Read More
Importance of Molecular Imaging in Patients With Prostate Cancer
December 21st 2022In an interview with Targeted Oncology, Channing J. Paller, MD, discussed the current approaches to radiation therapy, androgen deprivation therapy, and molecular imaging for men with prostate cancer who have biochemical recurrence.
Read More